Andrew C Birkeland, MD
Otolaryngology · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Regents of the Univ of CA · 1,571 clinicians in this group
Hospitals listed: Marshall Medical Center · University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Birkeland’s office at (916) 734-3112 to ask if they take your plan before you enroll.
California Medical Board record
Licence A152853 · Current
Licensed to practise in California · since 2017 · expires 2027-08-31 · Cornell University Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marshall Medical CenterPlacerville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Marshall Medical CenterPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Marshall Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 8 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.99) · 532 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.46 to 1.26) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 181.35 (122.12 to 240.58) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.7 · 116 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 52 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 245 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 368 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.9 · 171 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.3 · 1,441 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.08 to 0.52) · 3,312 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 3,241 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.31 (1.98 to 6.63) · 546 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.32) · 122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.79) · 499 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.5 (0 to 16.61) · 124 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.8 (0.64 to 8.96) · 119 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.19 to 3.2) · 135 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.26 (0 to 1.13) · 2,770 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 40 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.56 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.9 · 263 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 9.2 · 381 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 384 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.1 (5 to 9.9) · 225 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.5 to 15) · 225 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.1 to 15.1) · 1,577 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 545 cases | No different | Jan 2024 – Dec 2024 |
What patients said (540 patients answered, 21% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$102,825
Medicare paid this office $102,825 for 224 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $20,868 | $1,159 |
| Return visit (30+ min) | 70 | $7,514 | $72 |
| New patient visit (45+ min) | 49 | $5,011 | $102 |
| Diagnostic exam of voice box using a flexible endoscope | 75 | $4,720 | $50 |
| New patient visit (60+ min) | 24 | $3,204 | $134 |
See all 9 services
| Removal of lymph nodes, muscle, and tissue of neck | 18 | $20,868 | $1,159 |
| Return visit (30+ min) | 70 | $7,514 | $72 |
| New patient visit (45+ min) | 49 | $5,011 | $102 |
| Diagnostic exam of voice box using a flexible endoscope | 75 | $4,720 | $50 |
| New patient visit (60+ min) | 24 | $3,204 | $134 |
| Long return visit (40+ min) | 21 | $2,354 | $107 |
| Short return visit (20+ min) | 28 | $1,630 | $48 |
| Ultrasound scan of head and neck soft tissue | 35 | $701 | $19 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 11 | $634 | $58 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 23 | More than 76% of doctors who do this |
| Removal of tissue | 1-10 | None |
| Skin biopsy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 1-10 | None |
Who their Medicare patients are
224 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 15% · Women 41% · Also on Medicaid 27% · Health risk score 1.84. Sicker patients than 9 in 10 peers; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 75% · Coronary heart disease 29% · Chronic kidney disease 26% · Diabetes 25% · COPD 22% · Depression 22% · Cancer 20% · Heart failure 16% · Atrial fibrillation 16% · Stroke 10% · Dementia 9%.
The office billed $730,475, Medicare allowed $133,135 and paid $102,825; for 611 services of 104 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 224 | 611 | 74 | 1.84 | $730,475 | $102,825 |
| 2023 | 240 | 695 | 73 | 1.76 | $865,083 | $130,312 |
| 2022 | 202 | 657 | 71 | 1.84 | $848,191 | $129,432 |
| 2021 | 189 | 623 | 70 | 1.62 | $852,745 | $131,988 |
| 2020 | 148 | 470 | 71 | 1.87 | $674,696 | $108,340 |
| 2019 | 101 | 258 | 72 | 1.92 | $352,185 | $51,294 |
| 2018 | 51 | 94 | 71 | 2.14 | $72,270 | $8,748 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Removal of lymph nodes, muscle, and tissue of neck | 27 | $31,564 | $1,169 |
| Return visit (30+ min) | 85 | $10,136 | $73 |
| New patient visit (60+ min) | 39 | $5,770 | $148 |
| Diagnostic exam of voice box using a flexible endoscope | 72 | $5,260 | $53 |
| New patient visit (45+ min) | 39 | $4,093 | $105 |
| Long return visit (40+ min) | 30 | $4,018 | $118 |
| Short return visit (20+ min) | 32 | $2,072 | $52 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,213 | $71 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,188 | $108 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $879 | $49 |
| Ultrasound scan of head and neck soft tissue | 14 | $319 | $21 |
2022: 8 services
| Removal of lymph nodes, muscle, and tissue of neck | 23 | $25,527 | $1,110 |
| Return visit (30+ min) | 98 | $11,552 | $75 |
| Long return visit (40+ min) | 45 | $6,512 | $116 |
| New patient visit (60+ min) | 41 | $5,863 | $143 |
| Diagnostic exam of voice box using a flexible endoscope | 52 | $3,566 | $51 |
| New patient visit (45+ min) | 25 | $2,552 | $102 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 20 | $1,462 | $61 |
| Ultrasound scan of head and neck soft tissue | 29 | $757 | $22 |
2021: 9 services
| Removal of lymph nodes, muscle, and tissue of neck | 21 | $24,175 | $1,051 |
| Return visit (30+ min) | 65 | $8,054 | $79 |
| Long return visit (40+ min) | 33 | $5,274 | $123 |
| New patient visit (60+ min) | 29 | $4,214 | $145 |
| Diagnostic exam of voice box using a flexible endoscope | 57 | $3,374 | $50 |
| New patient visit (45+ min) | 28 | $3,188 | $114 |
| Short return visit (20+ min) | 32 | $1,639 | $47 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 26 | $1,544 | $57 |
| Ultrasound scan of head and neck soft tissue | 30 | $728 | $23 |
2020: 9 services
| Removal of lymph nodes, muscle, and tissue of neck | 17 | $17,634 | $1,037 |
| New patient visit (45+ min) | 38 | $3,901 | $103 |
| Long return visit (40+ min) | 23 | $3,200 | $94 |
| Return visit (30+ min) | 27 | $3,008 | $64 |
| Diagnostic exam of voice box using a flexible endoscope | 44 | $2,677 | $51 |
| New patient visit (30+ min) | 15 | $947 | $63 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 13 | $857 | $61 |
| Ultrasound scan of head and neck soft tissue | 27 | $645 | $23 |
| Short return visit (20+ min) | 12 | $604 | $43 |
2019: 4 services
| New patient visit (45+ min) | 20 | $2,104 | $105 |
| Diagnostic exam of voice box using a flexible endoscope | 27 | $1,344 | $50 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 20 | $901 | $35 |
| Return visit (30+ min) | 12 | $777 | $60 |
2018: 2 services
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $1,014 | $35 |
| Short return visit (20+ min) | 11 | $553 | $46 |
Drugs they prescribed that Part D paid
$2,277
Pharmacies billed $2,277 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
121 generic and fewer than 11 brand-name prescriptions · $2,277 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pentoxifylline | 32 | $758 | $24 |
| Levothyroxine | 14 | $160 | $11 |
| Gabapentin | 11 | $111 | $10 |
| Chlorhexidine Gluconate | 14 | $13 | $1 |
Year by year
| 2024 | 131 | 40 | None | None | $2,277 |
| 2023 | 152 | 45 | None | None | $7,593 |
| 2022 | 140 | 36 | 9% (13) | None | $7,351 |
| 2021 | 103 | 30 | None | 12% | $4,343 |
| 2020 | 37 | 20 | None | None | $1,147 |
| 2019 | 20 | 14 | None | None | $266 |
| 2018 | 38 | 26 | 34% (13) | None | $954 |
| 2017 | 48 | 29 | 42% (20) | None | $735 |
| 2016 | 57 | 39 | 53% (30) | None | $1,017 |
| 2015 | 12 | 11 | None | None | $273 |
| 2014 | 71 | 34 | 37% (26) | None | $2,081 |
| 2013 | 135 | 69 | 39% (53) | None | $4,556 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Pentoxifylline | 48 | $3,121 | $65 |
| Levothyroxine | 31 | $563 | $18 |
| Gabapentin | 20 | $347 | $17 |
| Chlorhexidine Gluconate | 17 | $44 | $3 |
2022: 4 drugs
| Pentoxifylline | 34 | $1,727 | $51 |
| Gabapentin | 17 | $494 | $29 |
| Levothyroxine | 16 | $351 | $22 |
| Chlorhexidine Gluconate | 26 | $66 | $3 |
2021: 4 drugs
| Pentoxifylline | 18 | $824 | $46 |
| Levothyroxine | 25 | $514 | $21 |
| Gabapentin | 11 | $328 | $30 |
| Chlorhexidine Gluconate | 18 | $50 | $3 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 15 | $225 | $15 |
2016: 1 drug
| Hydrocodone-Acetaminophen | 25 | $271 | $11 |
2014: 1 drug
| Hydrocodone-Acetaminophen | 12 | $122 | $10 |
2013: 2 drugs
| Oxycodone | 13 | $513 | $39 |
| Hydrocodone-Acetaminophen | 37 | $479 | $13 |
Money from drug and device companies
$141 in 2025
| 2025 | 2 | 3 | None | $141 |
| 2024 | 4 | 4 | None | $453 |
| 2023 | 1 | 1 | $3,088 | $3,088 |
| 2020 | 1 | 1 | None | $77 |
| 2019 | 2 | 4 | None | $4,652 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| DePuy Synthes Sales | Trumatch | $98 | 2 payments
|
| Medtronic | Ligasure | $44 | 1 payment
|
See all 3 published payments
| Medtronic | Meals · 2025-12-17 | Ligasure | $44 |
| DePuy Synthes Sales | Meals · 2025-06-22 | Trumatch | $69 |
| DePuy Synthes Sales | Meals · 2025-05-31 | Trumatch | $29 |
See earlier years (2024, 2023, 2020, 2019)
2024: $453
| Inspire Medical Systems | Inspire | $125 | 1 payment
|
| Genzyme | Dupixent | $120 | 1 payment
|
| Integra LifeSciences | Integra | $117 | 1 payment
|
| DePuy Synthes Sales | Trumatch | $91 | 1 payment
|
2023: $3,088
| EMD Serono | None | $3,088 | 1 payment
|
2020: $77
| DePuy Synthes Sales | Trumatch | $77 | 1 payment
|
2019: $4,652
| Intuitive Surgical | Da Vinci Surgical System | $4,564 | 3 payments
|
| DePuy Synthes Sales | Trumatch | $88 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · First-in-Human, Phase 1,1b, Open-Label, Multicenter Study of Bifunctional Egfr,Tgf Fusion Protein Bca101 Monotherapy and in Combination Therapy in Patients With Egfr-Driven Advanced Solid Tumors · 2025 | Their institution | $170,774 |
Professional record
- NPI
- 1700149317
- Licence
- CA A152853California A152853: Current · expires 2027-08-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207YP0228X (207YP0228X)
- Mailing address
- 900 Blake Wilbur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2012-06-19
- NPI last updated
- 2018-07-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1500 E Medical Center Dr, Ann Arbor, MI, 48109